Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-08634404 plus atezolizumab and chemotherapy in extensive-stage small cell lung cancer
jRCT2031250576Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Feb 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised trial of PF-08634404 in small cell lung cancer (SCLC) (2 arms), sponsored by Pfizer. Primary endpoints: Phase 2: Confirmed Objective Response Rate (ORR) per RECIST 1.1 (investigator assessment), Phase 2: Number of participants with treatment-emergent adverse events and 1 more. Started Feb 2026; status: recruiting.
02
Drugs
PF-08634404
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on jRCT2031250576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250576.